Vertex Pharmaceuticals SG&A increased by 1.4% to $493.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.5%, from $396.40M to $493.70M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 20.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $194.67M | $198.19M | $255.17M | $215.20M | $215.30M | $246.80M | $267.40M | $241.10M | $262.60M | $263.80M | $369.10M | $342.70M | $372.20M | $371.80M | $377.60M | $396.40M | $424.60M | $445.10M | $487.00M | $493.70M |
| QoQ Change | — | +1.8% | +28.7% | -15.7% | +0.0% | +14.6% | +8.3% | -9.8% | +8.9% | +0.5% | +39.9% | -7.2% | +8.6% | -0.1% | +1.6% | +5.0% | +7.1% | +4.8% | +9.4% | +1.4% |
| YoY Change | — | — | — | — | +10.6% | +24.5% | +4.8% | +12.0% | +22.0% | +6.9% | +38.0% | +42.1% | +41.7% | +40.9% | +2.3% | +15.7% | +14.1% | +19.7% | +29.0% | +24.5% |
Range$194.67M – $493.70M
CAGR+21.6%
Avg YoY Growth+21.8%
Median YoY Growth+20.8%
Current Streak6 quarters growth
SG&A at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's sg&a?
- Vertex Pharmaceuticals (VRTX) reported sg&a of $493.70M in Q1 2026.
- How has Vertex Pharmaceuticals's sg&a changed year-over-year?
- Vertex Pharmaceuticals's sg&a increased by 24.5% year-over-year, from $396.40M to $493.70M.
- What is the long-term trend for Vertex Pharmaceuticals's sg&a?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's sg&a has grown at a 20.2% compound annual growth rate (CAGR), from $840.10M to $1.75B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.